TY - JOUR
T1 - Significant differences in coeliac immunotoxicity of barley varieties
AU - Comino, Isabel
AU - Real, Ana
AU - Gil-Humanes, Javier
AU - Pistón, Fernando
AU - de Lorenzo, Laura
AU - Moreno, Ma de Lourdes
AU - López-Casado, Miguel Ángel
AU - Lorite, Pedro
AU - Cebolla, Ángel
AU - Torres, Ma Isabel
AU - Barro, Francisco
AU - Sousa, Carolina
PY - 2012/11
Y1 - 2012/11
N2 - Scope: The only treatment available for coeliac disease (CD) is a strict diet in which the intake of wheat, barley, rye, or oats is avoided. Barley is a major cereal crop, grown mainly for its use in brewing, and it has high nutritional value. The identification of varieties with a reduced toxicity profile may contribute to improve the diet, the quality of life and health of CD patients. Methods and results: Searching for harmless barleys, we investigated accessions of malting and wild barley, used for developing new cultivated cereals. The CD toxicity profile of barleys was screened using G12 antibody and cell proliferation and IFN-γ release from peripheral blood mononuclear cells and intestinal biopsies from CD patients. We found a direct correlation between the reactivity with G12 and the immunogenicity of the different barleys. Conclusion: The malting barleys were less immunogenic, with reduced levels of toxic gluten, and were possibly less harmful to CD patients. Our findings could raise the prospect of breeding barley species with low levels of harmful gluten, and the attractive goal of developing nontoxic barley cultivars, always taking into account the Codex standard for foods for special dietary use for persons intolerant to gluten.
AB - Scope: The only treatment available for coeliac disease (CD) is a strict diet in which the intake of wheat, barley, rye, or oats is avoided. Barley is a major cereal crop, grown mainly for its use in brewing, and it has high nutritional value. The identification of varieties with a reduced toxicity profile may contribute to improve the diet, the quality of life and health of CD patients. Methods and results: Searching for harmless barleys, we investigated accessions of malting and wild barley, used for developing new cultivated cereals. The CD toxicity profile of barleys was screened using G12 antibody and cell proliferation and IFN-γ release from peripheral blood mononuclear cells and intestinal biopsies from CD patients. We found a direct correlation between the reactivity with G12 and the immunogenicity of the different barleys. Conclusion: The malting barleys were less immunogenic, with reduced levels of toxic gluten, and were possibly less harmful to CD patients. Our findings could raise the prospect of breeding barley species with low levels of harmful gluten, and the attractive goal of developing nontoxic barley cultivars, always taking into account the Codex standard for foods for special dietary use for persons intolerant to gluten.
KW - 33-mer
KW - Barley
KW - Coeliac disease
KW - Interferon-gamma
KW - Monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=84867977505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867977505&partnerID=8YFLogxK
U2 - 10.1002/mnfr.201200358
DO - 10.1002/mnfr.201200358
M3 - Article
C2 - 22968973
AN - SCOPUS:84867977505
SN - 1613-4125
VL - 56
SP - 1697
EP - 1707
JO - Molecular Nutrition and Food Research
JF - Molecular Nutrition and Food Research
IS - 11
ER -